Kyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drug

Kyorin Pharmaceutical is paying $12 million upfront for the Japan rights to Edesa Biotech’s anti-TLR4 antibody to treat acute respiratory distress syndrome.